Overview
Precision HEOR provides consulting in health economics and outcomes research for biotech and pharmaceutical clients. They help demonstrate the value of innovations through economic modeling, evidence synthesis, and real-world data analysis. They translate clinical and economic data into value messages for regulators, payers, and providers to guide market access and commercialization. Their approach emphasizes rigorous HEOR methods and tailored guidance to support product development and decision making.
Work here?Claim your company
Simplify's Take
What believers are saying
- Precision AQ’s February 17, 2026 leadership expansion targets AI, data strategy, and evidence synthesis.
- The 2026 website still spotlights HEOR and payer strategy, signaling ongoing demand.
- Precisionheor content on IRA and gene therapy shows continued need for early value modeling.
What critics are saying
- HEOR consulting commoditizes as Precision AQ bundles pricing, IR, communications, and analytics.
- Precisionheor’s standalone identity weakened after the 2024 Precision AQ rebrand.
- Pharma budget cuts would quickly hit utilization; a prolonged slump threatens a consulting-dependent business.
What makes PRECISIONheor unique
- Precisionheor sits inside Precision AQ’s nine-brand life-sciences commercialization platform since May 2024.
- Its 95-plus researchers combine HEOR, epidemiology, biostatistics, and real-world evidence skills.
- 2025 SCHOLAR-2 work shows active disease-specific evidence generation for oncology clients.
Help us improve and share your feedback! Did you find this helpful?